Skip to main content
Premium Trial:

Request an Annual Quote

Celera and Elitra Pharma Sequence Aspergillus Fumigatus

NEW YORK, May 7 – Elitra Pharmaceuticals on Monday announced the complete sequencing to a 10X depth of coverage of the Aspergillus fumigatus genome. The sequencing work was performed by Celera Genomics under exclusive agreement.

“Sequencing the entire Aspergillus genome is a major technical achievement, and will accelerate our efforts to characterize and file patents on essential gene drug targets in this organism,” J. Gordon Foulkes, Elitra executive vice president of research, said in a statement. “Celera's technical efficiency and professionalism in completing this sequencing project has been truly outstanding.”

A. fumigatus has approximately one third the number of genes present in humans, according to the company. The common fungus can cause life-threatening infection called aspergillus in people with compromised immune systems.

San Diego-based Elitra identifies, develops, and sells antimicrobial compounds targeted to gene products of pathogenic organisms. 

The Sanger Center is also engaged in sequencing A. fumigatus

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.